Lior Shaltiel
Chief Executive Officer at NUREXONE BIOLOGIC INC.
Net worth: 158 950 $ as of 30/05/2024
Lior Shaltiel active positions
| Companies | Position | Start | End |
|---|---|---|---|
| NUREXONE BIOLOGIC INC. | Director/Board Member | 14/06/2022 | - |
| Chief Executive Officer | 31/03/2021 | - | |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Director/Board Member | 31/03/2021 | - |
| Chief Executive Officer | 31/03/2021 | - |
Career history of Lior Shaltiel
Statistics
International
| Israel | 2 |
| Canada | 2 |
Operational
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
Sectoral
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| NUREXONE BIOLOGIC INC. | Health Technology |
| Private companies | 1 |
|---|---|
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Health Technology |
- Stock Market
- Insiders
- Lior Shaltiel
- Experience
